ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1614

Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial

Caroline Maindet1, Anne Dumolard2, Mélanie Veloso2, Mario Barmaki3, Rodrigue Deleens4, Raphaël Gonon-Demoulian5, Alberta Lorenzi-Pernot6, Mireille Michel-Cherqui7, Alain Serrie8, Stanislas Velliet9 and Jean-Luc Bosson2, 1University Hospital Grenoble Alpes, Grenoble, France, 2Grenoble Alpes University Hospital, Grenoble, France, 3Médipôle Lyon Villeurbanne, Lyon, France, 4Rouen University Hospital, Rouen, France, 5Montpellier University Hospital, Montpellier, France, 6Neurology private practice, Mornant, France, 7Foch hospital, Suresnes, France, 8Paris University Hospital, Paris, Guinea, 9Valenciennes hospital, Valenciennes, France

Meeting: ACR Convergence 2023

Keywords: clinical trial, fibromyalgia, pain, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Fibromyalgia is a chronic syndrome with symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, and cognitive impairment. While first-line recommendation for this pathology is non-drug therapies (Macfarlane et al., 2017), namely physical therapy, symptoms often prevent patients from exercising. Therapies that rely on the body’s endogenous opioid system thus present an interesting non-pharmacological method of helping patients. The objective of this trial was to assess the efficacy of an intervention combining a millimeter-wave emitting wristband (MMW) and a coaching program. Exposure of the peripheral nervous system to MMW has been shown to provide a neuromodulating effect, mediated by the release of various neurotransmitters, including endorphins. Endorphins have pain relief and parasympathetic modulation properties that can alleviate the symptoms of fibromyalgia patients. Coaching aims to improve treatment adherence and efficacy.

Methods: In a multicenter, randomized, controlled trial (ClinicalTrials.gov NCT05058092), 170 fibromyalgia patients (ACR 2016 criteria, Wolfe et al., 2016) ) with moderate or severe Fibromyalgia Impact Questionnaire score (FIQ, Bennett et al., 2009, score ≥ 39/100) were divided into 2 groups of immediate (IG) or delayed (DG) intervention. The IG (N=84) received the intervention immediately after groups were assigned, in addition to their usual care (UC). The DG (N=86) received the intervention with a delay of 3 months, intervention starting after assessment of the primary endpoint (M3). In both groups, patients first received MMW wristband treatment and coaching for 3 months, then wristband treatment alone for 3 months. The intervention consisted of using the wristband for three 30-minute sessions a day and receiving 4 coaching sessions including educational content on the intervention and training in the use of the device (D0), a usability assessment (D7) and a benefit assessment (M1 and M2). In the event of low benefit at M1 or M2, the wristband’s stimulation mode (power & duration) could be adapted. Efficacy of intervention was assessed by comparing the number of patients in both groups whose quality of life measurement on the FIQ significantly improved between inclusion and M3. A decrease in FIQ score of ≥14% is considered clinically significant (Bennett et al., 2009). FIQ scores of the 2 groups were also measured at 6 months (M6).

Results: At M3, 55.1% patients of IG improved their quality of life beyond 14%, compared with 35.9% in the DG, and this difference between the groups was statistically significant (p=0.021). On average, patients in the IG improved their FIQ score by 21.7%, versus 7.2% in the DG. Benefits observed in the IG were preserved at M6, patients in this group having used their device autonomously between M3 & M6.

Conclusion: The combination of MMW and coaching led to improvements in the quality of life of fibromyalgia patients superior to those obtained with UC after M3. This improvement was maintained at M6, while patients were using their wristband autonomously. This non-pharmaceutical therapy offers patients a therapy they can use independently and on an outpatient basis.


Disclosures: C. Maindet: None; A. Dumolard: None; M. Veloso: None; M. Barmaki: None; R. Deleens: None; R. Gonon-Demoulian: None; A. Lorenzi-Pernot: None; M. Michel-Cherqui: None; A. Serrie: None; S. Velliet: None; J. Bosson: None.

To cite this abstract in AMA style:

Maindet C, Dumolard A, Veloso M, Barmaki M, Deleens R, Gonon-Demoulian R, Lorenzi-Pernot A, Michel-Cherqui M, Serrie A, Velliet S, Bosson J. Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/therapy-combining-millimeter-wave-based-neuromodulation-with-coaching-for-the-improvement-in-quality-of-life-of-patients-with-fibromyalgia-a-prospective-multicenter-randomized-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapy-combining-millimeter-wave-based-neuromodulation-with-coaching-for-the-improvement-in-quality-of-life-of-patients-with-fibromyalgia-a-prospective-multicenter-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology